TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06331442

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy
Description: Patients allocated to the first group (n=10) will receive photodynamic therapy. Buccal/labial surface around the bracket of each tooth in the upper dental arch (from right to left second premolar) will be treated with toluidine blue based dye (155 mg/mL; LaserHF Paro-PDT, Hager \& Werken, GmbH \& Co. Kg, Duisburg, Germany). This photosensitive solution will be applied on teeth with the sterile syringe and left for 60 s. Then, the excess of the photosensitive solution will be rinsed with the sterile syringe containing a saline solution. Then, a 660 nm diode laser (Laser HF, Hager \& Werken, GmbH \& Co. Kg, Duisburg, Germany) will be used for photoactivation (power output 100 mW, power density 124.34 W/cm2 and continuous working mode). Buccal/labial surface of each tooth will be radiated for 60 s at approximately 5 mm away from the enamel surface. This intervention will be performed right after the placement of a fixed orthodontic appliance (T0), 6 weeks (T1) and 12 weeks (T2) later.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tricalcium phosphate (TCP) varnish with 5% NaF
Description: Tricalcium phosphate varnish with 5% NaF (Clinpro™ White Varnish, 3M ESPE 3M Deutschland GmbH, Germany) will be applied to the patients allocated to the second group (n=10). The varnish will be applied to the buccal/labial surfaces of 10 teeth in the upper dental arch (from right to left second premolar) according to the manufacturer's recommendations. This intervention will be performed right after the placement of a fixed orthodontic appliance (T0), 6 weeks (T1) and 12 weeks (T2) later.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine varnish
Description: Chlorhexidine varnish (1% CHX, 1% thymol; Cervitec® Plus, Ivoclar Vivadent AG, Schaan, Liechtenstein) will be applied to the patients allocated to the third group (n=10). The varnish will be applied to the buccal/labial surfaces of 10 teeth in the upper dental arch (from right to left second premolar) according to the manufacturer's recommendations. This intervention will be performed right after the placement of a fixed orthodontic appliance (T0), 6 weeks (T1) and 12 weeks (T2) later.
Study: NCT05642455

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Afamitresgene autoleucel
Description: Single infusion of afamitresgene autoleucel Dose: For subjects ≥10 kg to \<40 kg: starting dose of 0.025 - 0.200 x 10'9 transduced cells/kg. For subjects ≥40 kg 1.0x109 to 10x109 transduced by a single intravenous infusion
Study: NCT05259371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transcutaneous Pulsed Electrical Stimulation (Device: Nu Eyne M02)
Description: Pulse Electrical Stimulation Patients wear our clinical trial device 30mins once a day for 16weeks.
Study: NCT06143865

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Closed system aspiration
Description: Aspiration catheter; it is part of the ventilator and the ventilator circuit. The catheter is stored in a protective sheath. Therefore, the catheter can be used repeatedly during the day.
Study: NCT04898062

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CRP-apheresis
Description: The major advantages of depleting C-reactive protein by therapeutic apheresis are the selective removal of the damaging agent by the highly specific ligand and the good controllability of the procedure, since the plasma can be passed over the column as often as necessary to achieve the desired reduction. In addition, treatment can be interrupted or discontinued at any time.
Study: NCT05896631

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 7.5 mg hyperbaric bupivacaine
Description: Spinal anesthesia with 7.5 mg hyperbaric bupivacaine after preoperative peng (pericapsular nerve group) block

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 5 mg hyperbaric bupivacaine
Description: Spinal anesthesia with 5 mg hyperbaric bupivacaine after preoperative peng (pericapsular nerve group) block
Study: NCT06308874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amg dose administration group
Description: Orally, Amg tablet single administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Amg dose administration group- Placebo
Description: Orally, Placebo Amg tablet single administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bmg dose administration group
Description: Orally, Bmg tablet single administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bmg dose administration group- Placebo
Description: Orally, Placebo Bmg tablet single administration
Study: NCT05183867

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Healthy Minds Program
Description: HMP is a 4-week mobile health (mHealth) meditation training program.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Minds Program
Description: HMP is a 4-week mobile health (mHealth) meditation training program.
Study: NCT05336162

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self etch giomer based fissure sealant (BeautiSealant, Shoufu, USA)
Description: A fissure sealant providing a physical barrier that inhibits microorganisms and food particles accumulation, preventing caries initiation, and arresting caries progression

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Self etch giomer based fissure sealant (BeautiSealant, Shoufu, USA)
Description: A fissure sealant providing a physical barrier that inhibits microorganisms and food particles accumulation, preventing caries initiation, and arresting caries progression
Study: NCT04448535

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Gingko Biloba
Description: oral intake of Gingko Biloba, 240mg/day for 4 weeks
Study: NCT05468229

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dorzagliatin
Description: single oral dose of dorzagliatin 50 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study: NCT06365723

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Green Walk
Description: All participants will be asked to walk three to five times per week for 30-50 minutes per walk, totaling 150 min/week, at moderate intensity over a 6-week period in a designated 'Green' urban environment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Green Walk
Description: All participants will be asked to walk three to five times per week for 30-50 minutes per walk, totaling 150 min/week, at moderate intensity over a 6-week period in a designated 'Green' urban environment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gray Walk
Description: All participants will be asked to walk three to five times per week for 30-50 minutes per walk, totaling 150 min/week, at moderate intensity over a 6-week period in a designated 'Gray' urban environment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gray Walk
Description: All participants will be asked to walk three to five times per week for 30-50 minutes per walk, totaling 150 min/week, at moderate intensity over a 6-week period in a designated 'Gray' urban environment.
Study: NCT05412732

Intervention type: OTHER
Intervention: prospective biomedical research study
Description: A prospective biomedical study, in which a comparison will be made of the outcome of a specific disease (in this case, AMI).

Intervention type: OTHER
Intervention: prospective biomedical research study
Description: A prospective biomedical study, in which a comparison will be made of the outcome of a specific disease (in this case, AMI).
Study: NCT05515705

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EUS navigation system
Description: Incorporation of the EUS navigation system to the EUS scope

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EUS navigation system
Description: Incorporation of the EUS navigation system to the EUS scope
Study: NCT05262699

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibro-tactile stimulation
Description: Vibro-tactile stimulation will be administered to the fingers of the participants via C3 tactors (diameter: 2.03 cm, height: 0.64 cm, operating frequency: 180-320 Hz, see https://www.eaiinfo.com/tactor-info/). Vibro-tactile stimulation will be triggered by force-sensing resistors (TEA CAPTIV T-SENS FSR, see https://www.teaergo.com/products/tea-captiv-t-sens-fsr/).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Control
Description: Devices mounted, no stimulation
Study: NCT06489600

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No Rays, Thanks Mineral sunscreen
Description: Wash your face with standard facewash and apply a pea size amount on the face in the morning.~Dosage form: semi-solid frequency: Once in a day Route of Administration: Topical
Study: NCT05092919

Intervention type: OTHER
Group type: OTHER
Intervention: Flavor
Description: Sweet flavored vs. non-flavored cigarillos.
Study: NCT06466031

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI & PET fusion
Description: MRI+T1C in fusion with MET-PET will be used for tumor resection and/or radiotherapy planning. Resection will be terminated after removal of PET-assigned tumor margin or in case any neuromonitoring-based indications regarding neurological damage occur.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI & PET fusion
Description: MRI+T1C in fusion with MET-PET will be used for tumor resection and/or radiotherapy planning. Resection will be terminated after removal of PET-assigned tumor margin or in case any neuromonitoring-based indications regarding neurological damage occur.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI+T1C
Description: MRI+T1C will be used for tumor resection and radiotherapy planning. Resection will be terminated after removal of contrast-enhancing part regardless of 5-ALA fluorescence or in case any neuromonitoring-based indications regarding neurological damage occur.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: MRI+T1C
Description: MRI+T1C will be used for tumor resection and radiotherapy planning. Resection will be terminated after removal of contrast-enhancing part regardless of 5-ALA fluorescence or in case any neuromonitoring-based indications regarding neurological damage occur.
Study: NCT06098365

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: segmental cervical stabilization exercises
Description: Segmental spine stabilization exercises were composed of axial extension, cervical extension exercises, cervico-scapulothoracic strengthening and cranio-cervical flexion exercises.

Intervention type: OTHER
Group type: OTHER
Intervention: cervical isometric exercises
Description: Cervical isometric exercises consist of 6 sets in a sitting position, each movement lasting 10 seconds, each repeated 5 times, with a 5-second rest in between.
Study: NCT05905120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toludivenlafaxine hydrochloride sustained-release tablets
Description: 80 mg/tablet, 2 tablets each time, once a day, for 4 days, orally at 30 min after the start of meals, 200 mL water to take
Study: NCT04956003

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 45-minute daily physical activity
Description: 45-minute daily physical activity session as an integral part of learning (during regular school sessions)
Study: NCT05486520

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging (MRI)
Description: MR images will be acquired using an ultra-low magnetic field 6.5 mT scanner located at the Martinos Center. The study time is estimated to be a maximum of 90 minutes with a maximum of 60 minutes of imaging time

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)
Description: MR images will be acquired using an ultra-low magnetic field 6.5 mT scanner located at the Martinos Center. The study time is estimated to be a maximum of 90 minutes with a maximum of 60 minutes of imaging time
Study: NCT06082141

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transversus thoracis plane block combined with serratus anterior plane block
Description: SAP block will be made with 10 ml 0.5% bupivacaine + 10 ml NaCl under US-guidance, TTP block will be made with 5 ml 0.5% bupivacaine + 5 ml NaCl under US-guidance

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Serratus anterior plan block
Description: SAP block will be made with 10 ml 0.5% bupivacaine + 10 ml NaCl under US-guidance, TTP block will be made with 10 ml NaCl under US-guidance
Study: NCT05961995

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Heartfulness meditation
Description: Heartfulness meditation is a secular, specific, guided meditation technique that includes progressive relaxation with a concentrated focus on the heart.
Study: NCT05040724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin
Description: ivermectin placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ivermectin
Description: ivermectin placebo
Study: NCT04804514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KH001
Description: The study drug is applied to teeth

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo is applied to teeth
Study: NCT05843851

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Diagnostic test
Description: Test for two mutations in the CTNS gene and one mutation in the PH1 gene and PH 3.
Study: NCT05666336

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Telitacicept
Description: It is necessary and will be given by subcutaneous injection of 160mg/week for 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: It is necessary and will be given by oral administration of 0.2g/day for 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: It is permitted which can be interchangeable with methylprednisolone. It will be given by oral administration of 30mg/day from beginning and be lowed dosage during the treatment of 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: It is permitted which can be interchangeable with prednisone. It will be given by oral administration of 24mg/day from beginning and be lowed dosage during the treatment of 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: It is permitted which can be interchangeable with mycophenolate mofetil or tacrolimus. It will be given by oral administration of 0.8g/month for 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: It is permitted which can be interchangeable with cyclophosphamide or tacrolimus. It will be given by oral administration of 0.5g twice a day for 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: It is permitted which can be interchangeable with cyclophosphamide or mycophenolate mofetil. It will be given by oral administration of 1mg twice a day for 24 weeks.
Study: NCT05717842

Intervention type: RADIATION
Intervention: Nuclear Medicine Scan
Description: Mercaptoacetyltriglycine 3 (Mag 3) Nuclear Medicine Scan
Study: NCT05784636

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-invasive BiPAP ventilation
Description: Patients were first treated with HFNC (High-flow nasal cannula) on the basis of conventional treatment. The initial parameters were temperature: 31-37 °C, flow rate: 30-40l /min, maintaining SpO2\>92%, adjusting oxygen concentration according to blood oxygen saturation, and treatment duration was 24 h. After 24 h, patients were treated with non-invasive ventilator-assisted ventilation BiPAP mode until discharge.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-invasive BiPAP ventilation
Description: Patients were first treated with HFNC (High-flow nasal cannula) on the basis of conventional treatment. The initial parameters were temperature: 31-37 °C, flow rate: 30-40l /min, maintaining SpO2\>92%, adjusting oxygen concentration according to blood oxygen saturation, and treatment duration was 24 h. After 24 h, patients were treated with non-invasive ventilator-assisted ventilation BiPAP mode until discharge.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HFNC
Description: On the basis of conventional treatment, patients were first administered a noninvasive ventilator with the following initial parameters. BiPAP mode with an initial inspiratory pressure (IPAP) of 8-15 cmH2O and an initial expiratory pressure (EPAP) of 4-8 cmH2O. These parameters were adjusted according to the patient's specific conditions. After 24 hours of treatment, patients received HFNC (High-flow nasal cannula) until discharge.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HFNC
Description: On the basis of conventional treatment, patients were first administered a noninvasive ventilator with the following initial parameters. BiPAP mode with an initial inspiratory pressure (IPAP) of 8-15 cmH2O and an initial expiratory pressure (EPAP) of 4-8 cmH2O. These parameters were adjusted according to the patient's specific conditions. After 24 hours of treatment, patients received HFNC (High-flow nasal cannula) until discharge.
Study: NCT04227314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast
Description: Apremilast: 30 mg twice daily during a 12 week double blind placebo controlled period, then 30 mg twice daily during an additional 12 week active treatment period

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo: 30 mg twice daily during the initial 12 week double blind placebo controlled period,
Study: NCT06245876

Intervention type: OTHER
Intervention: Blood collection
Description: Blood collection

Intervention type: OTHER
Intervention: Blood collection
Description: Blood collection

Intervention type: OTHER
Intervention: Blood collection
Description: Blood collection
Study: NCT04878770

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical corticosteroids
Description: Topical corticosteroids (TCS) are registered for patients of all ages, and are together with emollients, the pillars in the basic treatment of atopic dermatitis. In this study, patients in both the intervention groups and control group are treated with daily emollients and a TCS of moderate to high potency if needed. Rescue medication with TCS of higher potency may be prescribed if basic therapy is inadequate in controlling AD symptoms.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical corticosteroids
Description: Topical corticosteroids (TCS) are registered for patients of all ages, and are together with emollients, the pillars in the basic treatment of atopic dermatitis. In this study, patients in both the intervention groups and control group are treated with daily emollients and a TCS of moderate to high potency if needed. Rescue medication with TCS of higher potency may be prescribed if basic therapy is inadequate in controlling AD symptoms.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical corticosteroids
Description: Topical corticosteroids (TCS) are registered for patients of all ages, and are together with emollients, the pillars in the basic treatment of atopic dermatitis. In this study, patients in both the intervention groups and control group are treated with daily emollients and a TCS of moderate to high potency if needed. Rescue medication with TCS of higher potency may be prescribed if basic therapy is inadequate in controlling AD symptoms.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Systemic cyclosporine
Description: Systemic cyclosporine A (CsA) is an immunosuppressive therapy and is a registered treatment for AD in adults. According to national guidelines, CsA is the first choice for systemic treatment in children with moderate-to-severe AD.~For CsA a starting dose of 4-5mg/kg/day is administered orally and then tapered down to 2-3mg/kg/day depending on clinical effect. Two doses will be taken at two fixed times per day. Treatment with systemic CsA will be continued for a total of 6 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Systemic dupilumab
Description: Dupilumab (DUPIXENT) is indicated for the treatment of children of 6 years and older with moderate-to-sever atopic dermatitis whos disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids. rm: Active Comparator: Systemic dupilumab Dupilumab (DUPIXENT) is administered as a solution by subdermal injection according to national guidelines, based on age and body weight.
Study: NCT06399523

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VR therapy
Description: Participants this group received additional VR therapy , with a total 20 sessions over a period of 4 weeks based on routine treatment.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: VR sham
Description: Participants in this group received additional VR sham(health education videos,a total of 20 health education videos over a period of 4 weeks) under virtual reality conditions on the basis of routine treatment.
Study: NCT06247436

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Branch Chained Amino Acids
Description: postoperative BCAA consumption
Study: NCT04852328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CUE-101
Description: CUE Biopharma will supply CUE-101, which will be provided free of charge to the patient.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CUE-101
Description: CUE Biopharma will supply CUE-101, which will be provided free of charge to the patient.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CUE-101
Description: CUE Biopharma will supply CUE-101, which will be provided free of charge to the patient.
Study: NCT04508400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosaprepitant,ondansetron, dexamethasone
Description: Participants will randomly assigned 1:1 to receive double-blind study drug ( fosaprepitant plus ondansetron with dexamethasone OR placebo plus ondansetron with dexamethasone). Fosaprepitant or placebo to fosaprepitant were supplied and administered in a blinded manner.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo ondansetron with dexamethasone
Description: placebo plus ondansetron with dexamethasone